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Abstract Genetic and epigenetic changes are at the root of all
cancers. The epigenetic component involves alterations of the
post-synthetic modifications of DNA (methylation) and histones
(histone posttranslational modifications, PTMs) as well as of
those of their molecular “writers,” “readers,” and “erasers.”
Noncoding RNAs (ncRNA) can also play a role. Here, we focus
on the involvement of histone alterations in cancer, in particular
that of the histone variant H2A.Z in the etiology of prostate
cancer. The structural mechanisms putatively responsible for
the contribution of H2A.Z to oncogenic gene expression pro-
grams are first described, followed by what is currently known
about the involvement of this histone variant in the regulation of
androgen receptor regulated gene expression. The implications
of this and their relevance to oncogene deregulation in different
stages of prostate cancer, including the progression toward an-
drogen independence, are discussed. This review underscores the
increasing awareness of the epigenetic contribution of histone
variants to oncogenic progression.
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1 Introduction
Prostate cancer is the fifth most commonly diagnosed cancer
worldwide [1] and the second leading cause of cancer-related
death in men in the USA [2]. Crucial to the molecular etiology
of this male cancer is the androgen receptor (AR), a member
of the nuclear receptor superfamily. AR is present in the
cytoplasm in its inactive form. Upon interaction with andro-
gen, it undergoes a conformational change that allows it to
homodimerize prior to binding to the DNA androgen response
elements (AREs) [3]. AREs consist of inverted hexameric
DNA half-site-like recognition sequences (5′-TGTTCT-3′)
spaced by 3 bp [4] that are localized within the promoter
and enhancer regions of AR-regulated genes. The ligand
bound AR recruits co-activator proteins, including chromatin
remodeling complexes that have histone posttranslational
modification (PTM) activity, as well as components of the
basic transcriptional machinery leading to gene expression.
One such co-activator is SNF2-related CBP activator protein
(SRCAP) that catalyzes the ATP-dependent incorporation of
H2A.Z–H2B heterodimers into chromatin [5–7] and whose
deregulation plays a critical role in prostate cancer [8].
Histone H2A.Z is a replacement histone variant that is
expressed throughout the entire cell cycle in a replication
independent way [9]. It is so far the only histone that has been
shown to be indispensable for survival in many organisms and
while only a single gene copy is present in invertebrates, two
distinct gene copies exist in vertebrates [10]. These encode
two functionally different H2A.Z-1 and H2A.Z-2 subtypes
[10, 11] that have recently been implicated in prostate cancer
[12].
As histone variants come into the limelight of epigenetic
regulation in cancer [13], this review discusses different as-
pects of one of the most structurally and functionally contro-
versial variants, H2A.Z [9], and its involvement in prostate
cancer.
2 Histones and cancer
Although many cancers have a genetic origin, most of them
are either additionally subject to or are the direct result of
epigenetic alterations as well. The role played by external
factors such as the environment, smoking, life style, and viral
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infection in cancer etiology, and progression have long been
recognized.
For many years, the molecular mechanisms underlying
such epigenetic effects were ascribed to alterations in the
pattern of DNA methylation [14, 15]. Only more recently
has the role of histone PTMs and histone variants started to
be fully appreciated [16, 17]. Histones can change the geno-
mic landscape through two main types of mechanisms: his-
tone PTMs (such as for instancemethylation) and replacement
histone variants (see below). In contrast to DNA that can only
be methylated and hydroxymethylated, histones have a wider
spectrum of PTMs and are present in all eukaryotic cells and
organisms from sponges to humans. DNA methylation is
highly restricted to certain metazoan groups [18]. Therefore,
it is not surprising that histones have taken the main stage of
epigenetic research.
The quest for a potential relationship between histones and
cancer started long ago. In 1954, it was observed that histones
from cancer cells exhibited an altered solubility and electro-
phoretic mobility [19]. Although the nature of these altered
properties remains somewhat unexplained, it nevertheless
pointed to the idea that histones from cancer cells can differ
from those from nonmalignant cells. The most recent demon-
stration of this idea is from the observation that histone muta-
tions drive pediatric glioblastoma [20]. Also, the link between
alterations in histone PTMs and cancer is now very strong and
experimentally well-documented. For instance, loss of
H4K16Ac and H4K20Me3 have been shown to be general
hallmarks of human cancer [21] and changes in the levels of
global histone PTMs can be used as predictors of prostate
cancer recurrence outcomes [22].
3 Epigenetic mechanisms of histones
From a structural point of view, histones can be classified into
core (H2A, H2B, H3, and H4) and linker histones (histones of
the H1 family). The former are responsible for wrapping the
DNA around an octameric histone core leading to the organi-
zation of the basic subunit of chromatin; the nucleosome core
particle. The latter bind to the linker regions connecting adja-
cent nucleosomes and further contribute to the folding of the
chromatin fiber. From a more functional perspective, histones
can be essentially classified into two major groups: replication
dependent (canonical histones) and replication independent
(histone variants) [9]. Replication dependent histones are
present in gene clusters [23] and are massively expressed
during S-phase of the cell cycle. They provide one of the best
examples of eukaryotic genes whose transcripts lack
polyadenylated tails, and they lack introns. With the advent
of new powerful spectrometry approaches, a plethora of ca-
nonical histone variant paralogs [24] have been identified in
different cells and tissues that differ among themselves by
only one or two amino acids (see for instance [25]). In con-
trast, replication independent histones are expressed at much
lower rates throughout the entire cell cycle. Their individual
single copy genes are at isolated positions on the chromo-
somes, their mRNAs are polyadenylated, and they contain
introns [23]. They can replace the canonical histones and are
usually referred to as replacement histone variants.
In addition to their own structural variability, all histones
are amenable to a large variety of PTMs. To date, at least 15
different kinds of physiologically relevant histone PTMs have
been described including: acetylation [26, 27], methylation
[27, 28], phosphorylation [29, 30], poly-ADP ribosylation
[31], ubiquitination [32], sumoylation [33], prolyl-
isomerization [34], glycosylation [35], glycation and oxida-
tion [36], crotonylation [37], biotynylation [38], succinylation
[39], malonylation [39], lysine deamination [40], and
glutathionylation [41]. Alterations of these histone marks
can have dire effects on development and are associated with
many varieties of cancers, including prostate cancer [42] (see
[43] for a database resource of epigenetic marks in prostate
cancer).
Histone PTMs can be classified into global long-range [44]
and specific PTMs. Long-range PTMs are widespread over
long genomic regions and often have important structural
effects of their own [44], whereas specific PTMs take place
locally at specific regions of genes (promoters and enhancers)
and can be present in a combinatorial fashion creating a
“code” [45] that can be deciphered by downstream effector
protein complexes that either repress or enhance transcription.
The concept of histones and their PTMs having an epige-
netic role and its potential involvement in carcinogenesis was
realized in the early 1970s [46, 47], but its full significance
was not appreciated until more recently. It has its roots in the
so-called “histone code” hypothesis [45] according to which,
specific histone PTMs by themselves or in a combinatorial
fashion, can operate as marks that can be “read” by transcrip-
tional effectors that regulate gene expression. How these
histone PTMs are inherited throughout cell division and hence
are true epigenetic marks are still a matter of controversy. Yet,
histone PTMs determine the chromatin landscape that differ-
entiates one tissue type from another and are critical for
development of the organism. This makes it easy to under-
stand the important implications that deregulation of such
signals may have in cancer [48]. Although initially ascribed
to histone PTMs, the “code” notion can be made inclusive of
histone variants which constitute an additional combinatorial
layer of complexity to histone epigenetics [9, 49, 50]. Like
with histone PTMs, changes in the histone variant composi-
tion have been shown to play a role in cancer [13, 51–53].
Alterations in the levels of expression of linker histone vari-
ants [54–56] and core histone variants (H2A.1 and H2A.2
[57–61], H2A.X [62, 63], and macro H2A [64, 65]) have been
observed in several types of cancers. Of particular interest is
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the recently described potential involvement of histone
H2A.Z in cellular proliferation [66] as it pertains to prostate
cancer progression and prognosis [8, 12, 67, 68].
4 Histone H2A.Z: two subtypes and a controversial role
Histone H2A.Z is a replacement variant that has an ancient
origin in the evolution of the histone H2A family [69, 70]. It is
present in yeast, and it is encoded by a single gene throughout
the invertebrate phyla [10]. Likely as a result of the whole
genome duplication that took place at the onset of vertebrate
evolution, it diversified into two genes with different pro-
moters, 5’ UTRs and intron/exon organization [10]. Such an
event probably led to a subfunctionalization of the encoded
proteins (H2A.Z-1 and H2A.Z-2) that differ by only three
amino acids [10, 11]. With the exception of yeast, H2A.Z
has been shown to be indispensable for survival in several
model organisms including the ciliate protozoan Tetrahymena
[71],Drosophila [72],Xenopus [73], andmice [74]. In the case
of mice, deletion of only the H2A.Z-1 gene was enough for
lethality, supporting the concept of a subfunctionalization of
the two vertebrate variants.
Intriguingly, experiments performed by several groups in
the early 2000s indicated that H2A.Z was shown to work as
both a transcriptional repressor and as an activator from a
broad functional perspective [75–77]. Once the dynamic in-
teractions between the nucleosome and the basic transcrip-
tional machinery began to be examined in further detail, it
became increasingly evident that H2A.Z plays a role in pois-
ing genes for transcription where it helps to recruit RNA pol II
to genes that need to be activated but is not in itself necessary
for ongoing transcriptional activity [78]. As discussed further
below, in many instances, activation of transcription may
involve eviction of H2A.Z-containing nucleosomes near the
transcription start site (TSS) of actively transcribing genes.
The seemingly contradictory idea that H2A.Z functions both
as an activator and a repressor of transcription was mirrored
by the early structural data. Initial studies carried out with
nucleosomes reconstituted in vitro using recombinant human
H2A.Z showed a destabilization of the nucleosome resulting
from H2A.Z-1–H2B dimers binding less tightly to the H3–H4
tetramer [79]. These results supported the evidence from the
crystallographic data [80] which showed a destabilization of
the interaction between the H2A.Z–H2B dimer and the H3–
H4 tetramer. However, further biophysical characterization
using native H2A.Z (consisting of a mixture of H2A.Z-1
and H2AZ-2 from chicken erythrocytes) revealed a slightly
more compact nucleosome organization with similar salt de-
pendent stability as the nucleosomes containing canonical
histones [81]. For a more detailed discussion on the issues of
the functional and structural controversy of H2A.Z, the reader
is referred to [9, 77, 82].
The explanation of the dual functional/structural role of
H2A.Z has remained elusive, but several observations have
been made over the years that may in themselves or in com-
bination with one another shed some light on the problem (see
Fig. 1).
4.1 Histone posttranslational modifications
Whether H2A.Z acts as a repressor or an activator of tran-
scription may depend on its own PTMs and on those of the
histones associated with nucleosomes containing this variant.
For instance, a genome-wide analysis in yeast [83], chicken
[84], and several prostate cancer cell lines [68] demonstrated
that histone H2A.Z acetylation is found at promoters of ac-
tively transcribing genes and nonacetylated H2A.Z is present
at poised promoters of genes that are not actively undergoing
transcription. Also, H2A.Z-containing nucleosomes are often
enriched with marks of transcriptional activation such as tri-
methylated H3K4 [85]. More recently, it has been shown that
H2A.Z ubiquitination has an opposite effect [85] whereby this
H2A.Z PTM is found associated with facultative heterochro-
matin and plays an important role in the inactivation of the
human X-chromosome in female cells [85]. Both acetyla-
tion and ubiquitination marks of H2A.Z have been poten-
tially shown to play an important role in transcriptional
regulation by the AR [12, 67, 68] (Fig. 1) and deregulation
of histone acetylation and histone H2A.Z composition has
been shown in prostate cancer [12, 68]. From a structural
perspective, histone acetylation destabilizes the nucleosome
[86] and alters the binding of H2A.Z to chromatin [81],
which could facilitate the eviction of H2A.Z-containing
nucleosomes at promoter regions following transcriptional
activation (Fig. 1).
4.2 Homotypic and heterotypic H2A.Z nucleosomes
Each nucleosome consists of two H2A–H2B dimers.
Therefore, another possibility that could account for the func-
tional variability of H2A.Z is the presence of two H2A.Z–
H2B dimers within the same (homotypic) nucleosome or the
coexistence of an H2A–H2B and anH2A.Z–H2B dimer in the
same (heterotypic) nucleosome (Fig. 2). Despite initial claims
about the structurally unfavorable possibility of this latter
situation that was based on crystallographic data [80], evi-
dence has been provided for the existence of heterotypic
H2A.Z nucleosomes in the cell [87, 88] and for the ability of
these nucleosomes to be properly reconstituted in vitro
[89–91]. Furthermore, a genome-wide analysis recently car-
ried out in Drosophila showed that homotypic H2A.Z nucle-
osomes were enriched downstream of active gene promoters
[91]. Therefore, this hints at the possibility that the functional
role of H2A.Z-containing nucleosomes could be mediated by
its homo- or hetero-typic H2A.Z composition based on the
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assumption that the latter nucleosomes are potentially less
stable (Fig. 2) [91]. However, direct structural support of this
claim is missing and preliminary results do not seem to
support this notion.
4.3 Presence of multiple H2A.Z variants in vertebrates
Another alternative possibility regarding the multifaceted
function of H2A.Z, at least within the vertebrate lineage, could
be related to the presence in these organisms of two different
H2A.Z variants, H2A.Z-1, and H2A.Z-2, (Fig. 2) that have
been described at the beginning of this section [10, 11].
Despite the small amino acid sequence difference between
them, they exhibit a distinct electrophoretic mobility in SDS
polyacrylamide gel electrophoresis, which could suggest a
structural difference between them, and preliminary data in-
dicate that they may impart the nucleosome with different
structural [92] and functional [10, 12] properties. A pref-
erential increase of H2A.Z-1 was observed in castration
resistant lymph node carcinoma of the prostate (LNCaP)
xenograft tumors (a form of androgen independent tumor)
[12] (see below). However, a more direct experimental
evidence in support of the structural and functional differ-
ences imparted by these two H2A.Z variants is still
required.
4.4 Other possibilities
The mechanisms just described may act by themselves or in a
synergistic fashion. However, other factors may also be in-
volved. For instance, H2A.Z nucleosomes are refractory to
histone H1 binding [93]. While this may have little relevance
in yeast which contains only reduced amounts of H1, it may
be relevant within the context of mammalian cells. Also, the
presence of H2A.Z affects nucleosome mobility [94] and
positioning [93] in vitro and in situ [95] in a way that may
be DNA sequence dependent. This has led to a model where
the H2A.Z-mediated shift in nucleosome positioning at pro-
moters may have a repressing or activating action depending
on its occluding or permissive effect in allowing access to
regulatory DNA sequence elements [76].
5 Histone H2A.Z in androgen receptor regulated genes
The AR is a ligand-dependent transcription factor that is
critical for the development of the human male phenotype
and a major player in prostate cancer. Therefore, understand-
ing the molecular chromatin determinants of its involvement
in the regulation of gene expression is of critical relevance.
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Fig. 1 Schematic representation of the potential mechanisms involved in
the displacement of H2A.Z-containing nucleosomes during transcription-
al activation of androgen receptor regulated genes. a Histone de-
ubiquitination (mediated by USP-10) [67] and histone acetylation (medi-
ated by Tip 60 [97] are required for binding of AR to its AREs. Hetero-
typic H2A.Z nucleosomes at promoter regions (b) or H2A.Z-1 nucleo-
somes (c) may be less stable (more prone to dissociate, as indicated by the
thicker arrow in the double arrow sets) and hence facilitate nucleosome
removal. In this representation, H2A.Z-1 is shown in brownand H2A.Z-2
is in violet. Although shown separately here for clarity, it is possible that
some of these mechanisms take place at the same time or in a combina-
torial fashion. Generic histone H2A.Z (which includes the two variants) is
represented in redand acetylated histones including H2A.Z are highlight-
ed in yellow dashes. AR androgen receptor, ARE androgen responsive
element, Pol II RNA polymerase II. For simplicity, histone H1 has not
been shown in this representations
432 Cancer Metastasis Rev (2014) 33:429–439
Several transcriptional co-activators of AR have been de-
scribed to date. Some of them participate in the establishment
of histone PTMs that are critical for the overall activation
process. These include, HIV-1 TAT interactive protein 60
(Tip60), which acetylates histone lysines [96], as well as AR
itself [97] and ubiquitin-specific protease 10 (USP-10), which
specifically de-ubiquitinates H2A.Z [67]. Other activators are
involved in the incorporation of histone variants into chroma-
tin, such as SRCAP which in conjunction with Tip 60 has
been shown to catalyze the ATP-dependent incorporation of
H2A.Z–H2B dimers into chromatin at promoters and en-
hancers [5–7]. De-ubiquitination of H2A.Z by USP-10 and
acetylation of the histones neighboring the AREs (by Tip60)
in these regions (Fig. 1) are critical for the events that follow
the activation of the gene. Another important transcriptional
co-activator bromodomain-containing protein 2 (Brd2), which
has two bromodomains, has been more recently identified and
shown to bind to nucleosomes containing H2A.Z in a histone
H4 acetylated dependent manner [98]. However, the molecu-
lar role of Brd2 in transcriptional activation remains to be
elucidated.
Incorporation of H2A.Z mainly at the enhancer and prox-
imal promoter regions of the prostate-specific antigen gene
(PSA) poises the gene for activation by AR [12]. A similar
situation is likely to be present at other AR regulated genes,
and it is likely accompanied by DNA demethylation (Fig. 2a).
DNA hypomethylation has recently been shown to be associ-
ated with a tissue-specific enhancer landscape [99]. The pres-
ence of H2A.Z in these regions may further assist in the
establishment of histone H1 depleted and DNase I hypersen-
sitive (DHS) nucleosome-free regions [100, 101] as well as in
the positioning of nucleosomes at AR binding sites [102, 103].
All of this is likely to be essential for the nucleosome dynam-
ics assisting the full assembly of the transcriptional complex
containing RNA pol II (Fig. 2b). In this regard, recent litera-
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Fig. 2 The enhancer and promoter regions come in close proximity
during the process of gene activation in AR regulated genes. a The
process involves SRCAP, a well known co-activator of AR responsible
for the deposition of H2A.Z–H2B dimers into chromatin. SRCAP is an
integral part of a large ATP-dependent chromatin remodeling complex
which contains, among other subunits, the histone acetyltransferase
p300/CBP and the forkhead protein FoxA1. The resulting complex brings
RNA pol II to the transcriptional start site. Notice that in this proposed
model, incorporation of H2A.Z results in histone H1 exclusion [93],
demethylated DNA, and nucleosome depleted regions [106] that are
responsible for the presence of DHS domains [100, 101]. bThe activation
model proposed is based on several observations from different groups
and includes: presence of two positioned nucleosomes (shown in green) at
AR regulated enhancers [102, 103] that are brought in close proximity to
the promoter by chromatin looping [111], a process that likely involves
FoxA1 [112]. These nucleosomes are flanked by p300/CBP acetylated
chromatin domains spanning approximately 2,000 base pairs [102, 103].
The shadowed yellowwaves denote the distribution of histone acetylation
upon AR induction of gene expression
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CpG islands of previously hypermethylated tumor suppressor
genes results in nucleosome eviction [104] and an enhanced
chromatin accessibility [105]. Such a process has been shown
to be regulated by SRCAP-mediated H2A.Z insertion [106].
Indeed, H2A.Z is often found at promoters and enhancers
which display DHS [100, 107, 108]. AR binding takes place
at the AREs which are present at regulatory regions of AR
regulated genes (Fig. 2), primarily at enhancers. In prostate
cancer cells, androgen treatment results in the dismissal of a
central nucleosome [103] which is likely responsible for the
DHS associated with these regions [109] (Fig. 2).
Interestingly, in prostate cancer cells, such nucleosome deplet-
ed regions appear to be present already at some of ARr
enhancers in the absence of ligand in a “receptive” state for
histone modifiers. Binding of androgen to AR displaces the
equilibrium toward a DHS nucleosome-depleted state [110].
Further assembly of the basal transcriptional machinery com-
plex during the activation of AR regulated genes involves the
looping of chromatin [111] that brings together some of the
complexes assembled at the multiple AREs that are present in
the enhancers with the AREs at the promoter region (see
Fig. 2b). The process appears to be mediated by forkhead
box protein A1 (FoxA1) [112]. The complex brings with it
p300/CBP which acetylates chromatin domains of approxi-
mately 2000 bp [102, 103], and the enhancer AREs become
flanked by acetylated positioned nucleosomes [102] (Fig. 2b).
This sets up the stage for the initiation of transcription.
6 Altered expression of H2A.Z during prostate cancer
progression
Like many other cancers, prostate cancer is the result of
manifold genetic and epigenetic alterations. A recurrent theme
at the genetic level involves the presence of several gene
fusions [113] including a major translocation on chromosome
21 that fuses the AR regulated promoter of the transmembrane
protease, serine 2 (TMPRSS2) gene to oncogenic transcrip-
tion factor genes of the E-twenty six (ETS) family [114, 115].
Mutations, such as those of Fox A1, which suppress androgen
signaling and promote tumor growth, also play an important
role in the progression of prostate cancer to an androgen
independent state [116].
On the epigenetic front, in addition to changes in the
histone PTM landscape [22, 117, 118], other mechanisms
involved in the progression of prostate cancer to an androgen
independent state also include alterations in the DNA methyl-
ation patterns which, as with other cancer types [14, 15],
constitute one of the major hallmarks of prostate cancer and
its progression [119]. Both hyper- and global DNA hypome-
thylation have been described in the early stages and during its
progression, respectively [119–121]. Interestingly, over-
expression of the polycomb-group protein EZH2 (enhancer
of zeste homolog 2) has also been observed [122, 123]. EZH2
is a histone-lysine N-methyltransferase that methylates lysine
at position 27 of H3 and recruits DNA methyltransferases
[124]. This provides a connection between some of the histone
and DNA epigenetic mark alterations during the androgen-
dependent stages of prostate cancer [see PEpID [43]] [123,
125–127]. Deregulation of EZH2 has been described as a
mechanism for aberrant specific DNA methylation of the
genes involved in cancer [128]. In prostate cancer, DNA
hypermethylation is responsible for inactivation of key regu-
latory genes such as E-cadherin, pi-class glutathione S-
transferase, and the tumor suppressors CDKN2, PTEN, and
IGF-II [129].
Interestingly, an anticorrelation has been observed between
DNA methylation and the occurrence of H2A.Z in the ge-
nome, such that genomic regions that are enriched in DNA
methylation are often devoid of histone H2A.Z [130, 131].
Such correlations have implications for the chromatin envi-
ronment of the regions associated with AR.
Given the alterations in DNA methylation during the pro-
gression of prostate cancer [119], and the antagonistic relation-
ship between DNAmethylation and H2A.Z occupancy, it is not
surprising that a few recent papers have also implicated the
histone variant H2A.Z in this type of cancer [8, 12, 67, 68, 98].
Furthermore, inhibition of SRCAP expression has been shown
to interfere with the androgen-dependent stages of prostate
cancer cell growth [8]. As was seen with the expression of the
PSA gene [12], it was found that in prostate cancer cells there is
an H2A.Z reorganization that poises the oncogene promoters
for activation. The overall levels of H2A.Z decrease at the TSSs
of such promoters upon activation which is accompanied by a
gain of acetylated H2A.Z [68]. In this way, H2A.Z operates as a
facilitator of transcription that is evicted or subject to a rapid
dynamic turnover once the gene is undergoing cycles of tran-
scription in quick succession in the presence of androgen [12].
Histone H2A.Z appears to have several important roles
during the androgen independent stages of prostate cancer as
well. A significant increase in H2A.Z, mainly affecting the
H2A.Z.1 subtype, was observed in castration resistant LNCaP
xenograft tumors (a form of androgen-independent tumor)
[12]. Interestingly, the promoters of H2A.Z.1 and H2A.Z.2
are completely different where that of H2A.Z-1 contains sev-
eral myelocytomatosis viral oncogene (MYC) regulatory ele-
ments. These elements are likely responsible for the increase
in H2A.Z-1 expression observed in castration-resistant tumors
[12]. Indeed, the increasing levels of MYC in castration-
resistant prostate cancer [132] result in a global loss of
H3K27me3 [133] (Fig. 3) and hence a global decrease in
DNA methylation which is a characteristic feature of late- or
end-stage metastatic prostate cancer [134].
It is not possible to know whether the increase in H2A.Z-1
observed by Dryhurst et al.[12] in the transition to castration
resistant prostate cancer is required to mediate a specific
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cellular function during the transition to androgen indepen-
dence or if it is simply a by-product of a more aggressive and
advanced stage of cancer. As pointed out in [12], two possi-
bilities exist (Fig. 3).
We have already described how H3K27me3 is important
for the regulation of the levels (both specific and global) of
DNA methylation. A negative correlation has been found
between the aggressiveness of prostate cancer (Gleason score
and pathological state) and the global loss of H3K27me3
which is linked to MYC over-expression [133, 135] (Fig. 3).
Such an increase in MYC could also affect the activation of
the MYC-responsive H2A.Z.1 promoter. This would lead to
an over-expression of this histone variant which, given its
antagonistic relationship with DNAmethylation, could in turn
exacerbate the global DNA hypomethylation [12].
An alternative possibility could be that the increased ex-
pression of H2A.Z-1 would lead to an altered association of
this histone variant with chromatin which could increase the
plasticity of castration resistant cancer cells. Indeed, an AR
responsiveness persists in the androgen-dependent to -
independent transition of prostate cancer [136] and, with its
co-activator SRCAP, AR could potentially bring the over-
expressed H2A.Z.1 to different promoters. As H2A.Z is high-
ly enriched within the promoter regions of transcriptionally
active genes [108] such an alteration could potentially lead to
a completely altered program of gene expression (Fig. 3b).
Notably, it has been shown that AR induces a distinct tran-
scriptional program in androgen-independent prostate cancer
than in androgen-dependent prostate cancer [137, 138].
7 Concluding remarks and future perspectives
From all the above, H2A.Z appears to be an important player in
the regulation of AR regulated genes which has manifold roles
in the regulation of the structural chromatin transitions at the
base of the native and deregulated condition of such genes.
Hence, the involvement of H2A.Z in prostate cancer is not
surprising. Its active participation in the androgen-dependent
stages of the disease is clearly reflected by the dependence on
SRCAP for cell proliferation [8]. In contrast, EZH2-mediated
DNA methylation of tumor suppressor genes at these early
stages may simply prevent H2A.Z from binding and activation
of such genes. In the androgen-independent stages of this cancer,
the preferential binding of H2A.Z-2 to H3K4me3 [12] seems to
play an active role in directing AR to the M-phase cell cycle
genes [137, 139]. While this again suggests a causative involve-
ment, the connection between the further MYC-dependent
DNA hypomethylation and over-expression of H2A.Z-1, which
is also observed in the later androgen-independent stages, re-
mains to be determined. It is nevertheless clear that whatever the
causative and consequential nature of the effects elicited by
histone variant are, they are closely intertwined and critically
important for prostate cancer development and its progression.
Other examples of histone variant involvement in cancer
have also been described [56]. For instance, hisone H2A.Z has
also been shown to be involved in the regulation of ER-
dependent genes in breast cancer [53, 66, 95, 140, 141];
macroH2A has a tumor suppressive function [64, 142, 143].
Nevertheless the literature available is scarce, and it has not
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Fig. 3 A potential mechanism to explain the androgen-independent gene
expression program (a). An inactive gene in androgen-dependent prostate
cancer could be randomly activated in the androgen-independent stages
of cancer progression (b). SRCAPwould be involved in the deposition of
histone H2A.Z–H2B dimers resulting from the MYC-induced over-ex-
pression of H2A.Z-1 in androgen-independent prostate cancer cells [12].
As H2A.Z and DNA methylation have been shown to have an antago-
nistic genomic distribution [130, 144] and gene occupancy during B-cell
lymphomagenesis [131], increased H2A.Z-1 deposition would, in a sim-
ilar fashion, exacerbate the global DNA hypomethylation that has been
shown to be a feature of late-stage metastatic prostate cancer [134]
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been until very recently that histone variants have started
being perceived as “emerging players in cancer biology” [13].
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